Yoshikazu Takada

This study shows Galectin-3 binds to integrins αvβ3, αIIbβ3, and α5β1 in a glycan-independent manner and activates them through two distinct sites, with implications for inflammation and thrombosis.

This study shows ivermectin binds to the allosteric site 2 of integrins and inhibits their activation by pro-inflammatory cytokines, similar to anti-inflammatory cytokines.

This study identifies the heparin-binding domain of VEGF165 as critical for integrin αvβ3 binding and signaling, showing its role in mitogenic activity.

This study shows FGF2 activates integrin αIIbβ3 via site 2, while FGF1 binds site 2 but inhibits FGF2-induced activation, suggesting FGF1's anti-thrombotic mechanism.

This study shows FGF2 activates αvβ3 integrin via site 2, while FGF1 binds site 2 but suppresses integrin activation, suggesting FGF1's anti-inflammatory action is through blocking site 2.

This study identifies FGF9 as a new ligand for integrin αvβ3 and shows that a mutant defective in integrin binding acts as an antagonist by suppressing FGF9 signaling.